Isolation of the Neu HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells

Cell

Volumn 69, Issue 1, 1992, Pages 205-216

  Peles, Elior ^a   Bacus, Sarah S ^b   Koski, Raymond A ^c   Lu, Hsieng S ^c   Wen, Duanzhi ^c   Ogden, Steven G ^c   Levy, Rachel Ben ^a   Yarden, Yosef ^a  

^a Department of Chemical Immunology The Weizmann Institute of Science Rehovot ^*  (Israel)

^b Cell Analysis Systems Inc ^*  (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; LIGAND; NEU DIFFERENTIATION FACTOR;

ARTICLE; BREAST MILK; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CROSS LINKING; GROWTH INHIBITION; LACTATION; PHOSPHORYLATION; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN PURIFICATION;

AMINO ACID SEQUENCE; ANIMAL; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TRANSFORMED; ELECTROPHORESIS; GLYCOPROTEINS; HUMAN; MOLECULAR SEQUENCE DATA; NEUREGULINS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASE; PROTO-ONCOGENE PROTEINS; RATS; RECEPTOR, ERBB-2; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TUMOR CELLS, CULTURED;

EID: 0026776424     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/0092-8674(92)90131-U     Document Type: Article

References (62)

1. Differentiation of cultured breast cancer cells (AU-565 and MCF-7) associated with loss of cell surface HER-2/neu antigen
2. Tumor inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells
3. The neu oncogene encodes an epidermal growth factor receptor-related protein
4. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
5. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading
6. 125I-containing acylating agent
7. Epidermal growth factor
8. Demonstration of epidermal growth factor-induced receptor dimerization in living cells using a chemical crosslinking agent
9. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with Neu oncogene
10. Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned medium
11. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
12. Characterization of a neulc-erbB-2 protein-specific activating factor
13. γ and GTPase-activating protein does not correlate with erbB-2 ḿitogenic activity
14. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation
15. The pleiotropic actions of leukemia inhibitory factor
16. Eukaryotic protein kinases
17. Differential processing and turnover of the oncogenically activated neulerbB-2 gene product and its normal cellular counterpart
18. HER-2 causes transformation and tumorigenesis of NIH-3T3 cells
19. Gas-phase protein/peptide sequencing
20. Identification of multiple novel polypeptide substrates of v-src, v-yes, v-fps, v-ros and v-erbB oncogenic tyrosine protein kinases utilizing antisera against phosphotyrosine
21. The trk protooncogene product: a signal transducing receptor for nerve growth factor
22. Amplification of a novel v-erbB-related gene in a human mammary carcinoma
23. EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SKBR-3
24. Ligand-independent tyrosine phosphorylation of EGF-receptor and the erbB-2/neu protooncogene product is induced by hypertonic shock
25. The trkB proto-oncogene encod́es a receptor for nerve growth factor
26. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products
27. Expression of the EGF receptor-related protooncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms
28. Tumorigenic conversion of primary embryo fibroblasts requires at least two operating oncogenes
29. HER-2 cytoplasmic domain generates normal mitogenic and transforming signals in chimeric receptor
30. A chimeric EGF-R-neu protooncogene allows EGF to regulate neu tyrosine kinase and cell transformation
31. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand
32. erbB-2
33. Transforming growth factor β family
34. Transforming growth factor production by chemically transformed cells
35. Oncogenic forms of the neu/HER2 tyrosine kinase are permanently coupled to phospholipase C
36. Recent developments in the cell biology of basic fibroblast growth factor
37. New class of transforming growth factors potentiated by epidermal growth factor
38. The neu oncogene and erbB-2 related gene encoding a 185,000 Mr tumor antigen
39. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumors with constitutive milk protein gene transcription
40. HER-2 signal transduction in breast cancer cells
41. A v-erbB-related protooncogene c-erbB-2, is distinct from the c-erbB-1 epidermal growth factor-receptor gene and is amplified in human salivary gland adenocarcinoma
42. Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7
43. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/Neu oncogene
44. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer
45. Peptide growth factors are multifunctional
46. Mechanistic aspects of the opposing effects of monoclonal antibodies to ERBB2 receptor on tumor growth
47. neu: a potential model for receptor interactions
48. Epidermal growth factor receptor, platelet-derived growth factor receptor, and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation
49. Multiple hormone interactions in the developmental biology of the mammary gland
50. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene co-amplification units: HST-1/int-2 and c-erbB-2/erbB-1
51. Signal transduction by receptors with tyrosine kinase activity
52. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene
53. Alterations to either c-erbB-2 (Neu) or c-myc protooncogenes in breast carcinomas correlate with poor short-term prognosis
54. Over-expression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlated with gene amplification
55. neu protein and EGF receptor modulates EGF receptor function
56. Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor
57. Receptor like oncogenes: functional analysis through novel experimental approaches
58. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active
59. Biochemical analysis of the ligand for the Neu oncogenic receptor
60. Growth factor receptor tyrosine kinases
61. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the Neu protooncogene
62. Association of multiple copies of the c-erbB-2 oncogenes with spread of breast cancer